Ysios Capital leads a €51M round in Adcendo, also followed up by Novo Seeds, RA Capital Management, HealthCap and Gilde
ADCENDO RAISES €51 MILLION IN SERIES A FINANCING TO ADVANCE NOVEL ANTIBODY-DRUG CONJUGATES FOR TREATMENT OF CANCERS. Financing led by Novo Seeds and Ysios Capital is largest Series A for a Danish biotech company Plans to build a pipeline of ADCs directed at novel cancer targets…